Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication

@inproceedings{Bilger2017LeflunomideteriflunomideIE,
  title={Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication},
  author={Andrea Bilger and Julie Plowshay and Shidong Ma and Dhananjay Nawand ar and Elizabeth A. Barlow and James C Romero-Masters and Jillian A Bristol and Zhe Li and Ming-Han Tsai and Henri-Jacques Delecluse and Shannon C. Kenney},
  booktitle={Oncotarget},
  year={2017}
}
EBV infection causes mononucleosis and is associated with specific subsets of B cell lymphomas. Immunosuppressed patients such as organ transplant recipients are particularly susceptible to EBV-induced lymphoproliferative disease (LPD), which can be fatal. Leflunomide (a drug used to treat rheumatoid arthritis) and its active metabolite teriflunomide (used to treat multiple sclerosis) inhibit de novo pyrimidine synthesis by targeting the cellular dihydroorotate dehydrogenase, thereby decreasing… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 65 REFERENCES

The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.

  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2017

Teriflunomide for multiple sclerosis.

  • The Cochrane database of systematic reviews
  • 2016
VIEW 1 EXCERPT

EBV Persistence--Introducing the Virus.

  • Current topics in microbiology and immunology
  • 2015
VIEW 1 EXCERPT